Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Cash from Operations (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Cash from Operations for 8 consecutive years, with 71173000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations fell 78.68% year-over-year to 71173000.0, compared with a TTM value of 239725000.0 through Sep 2025, down 18.31%, and an annual FY2024 reading of 164724000.0, down 171.7% over the prior year.
  • Cash from Operations was 71173000.0 for Q3 2025 at Bicycle Therapeutics, up from 72786000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 34096000.0 in Q2 2023 and bottomed at 86370000.0 in Q1 2025.
  • Average Cash from Operations over 5 years is 29294000.0, with a median of 26400000.0 recorded in 2022.
  • The sharpest move saw Cash from Operations surged 317.51% in 2021, then tumbled 3786.05% in 2024.
  • Year by year, Cash from Operations stood at 10435000.0 in 2021, then tumbled by 190.46% to 30309000.0 in 2022, then crashed by 56.02% to 47288000.0 in 2023, then skyrocketed by 80.13% to 9396000.0 in 2024, then crashed by 657.48% to 71173000.0 in 2025.
  • Business Quant data shows Cash from Operations for BCYC at 71173000.0 in Q3 2025, 72786000.0 in Q2 2025, and 86370000.0 in Q1 2025.